论文部分内容阅读
目的探讨耐药基因产物P-糖蛋白(P-gp)与新辅助化疗治疗子宫内膜癌疗效的相关性。方法选择接受新辅助化疗的子宫内膜癌患者67例作为观察组,同期体检的68名健康妇女作为对照组。比较两组患者的P-gp表达情况。结果观察组P-gp阳性率为64.2%,对照组P-gp阳性率为1.5%;观察组P-gp表达阴性患者化疗后完全缓解(CR)11人,部分缓解(PR)11人,稳定(SD)1人,进展(PD)1人;P-gp表达阳性患者化疗后CR 13人,PR 8人,SD 19人,PD 3人。P-gp表达阴性患者的疗效显著高于P-gp表达阳性患者(z=2.550,P=0.011);P-gp表达阳性患者与P-gp表达阴性患者的临床病理因素比较,差异无统计学意义(P>0.05)。结论 P-糖蛋白与子宫内膜癌患者新辅助化疗的疗效密切相关。
Objective To investigate the relationship between drug-resistant gene P-glycoprotein (P-gp) and neoadjuvant chemotherapy in the treatment of endometrial cancer. Methods 67 cases of endometrial cancer receiving neoadjuvant chemotherapy were selected as the observation group and 68 healthy women in the same period as the control group. P-gp expression was compared between the two groups. Results The positive rate of P-gp in the observation group was 64.2%, and the positive rate of P-gp in the control group was 1.5%. In the observation group, there were 11 patients with complete remission (CR) and 11 partial remission (PR) (SD) and 1 patient with progression (PD). There were 13 CR patients, 8 PR, 19 SD patients and 3 PD patients with positive P-gp expression after chemotherapy. The curative effect of P-gp negative patients was significantly higher than that of P-gp positive patients (z = 2.550, P = 0.011). There was no statistical difference between P-gp positive patients and P-gp negative patients Significance (P> 0.05). Conclusion P-glycoprotein is closely related to the efficacy of neoadjuvant chemotherapy in patients with endometrial cancer.